2021 Q4 Form 10-K Financial Statement
#000095017022003946 Filed on March 16, 2022
Income Statement
Concept | 2021 Q4 | 2021 | 2020 Q4 |
---|---|---|---|
Revenue | $118.3M | $295.8M | $0.00 |
YoY Change | 185.98% | ||
Cost Of Revenue | $102.5M | $264.3M | |
YoY Change | |||
Gross Profit | $15.84M | $31.45M | |
YoY Change | |||
Gross Profit Margin | 13.39% | 10.63% | |
Selling, General & Admin | $18.93M | $45.53M | $3.741M |
YoY Change | 405.97% | 1035.04% | |
% of Gross Profit | 119.52% | 144.79% | |
Research & Development | |||
YoY Change | |||
% of Gross Profit | |||
Depreciation & Amortization | $6.070M | $2.800M | |
YoY Change | 226.34% | ||
% of Gross Profit | 38.33% | 8.9% | |
Operating Expenses | $25.02M | $324.6M | $3.741M |
YoY Change | 568.71% | 246.26% | |
Operating Profit | -$9.181M | -$28.82M | |
YoY Change | -397.69% | ||
Interest Expense | $6.830M | -$4.492M | -$17.54M |
YoY Change | -138.93% | 170.77% | |
% of Operating Profit | |||
Other Income/Expense, Net | -$495.0K | -$1.333M | |
YoY Change | |||
Pretax Income | -$3.397M | -$6.516M | -$21.28M |
YoY Change | -84.04% | -186.05% | |
Income Tax | $159.0K | $159.0K | |
% Of Pretax Income | |||
Net Earnings | -$3.556M | -$6.675M | -$21.28M |
YoY Change | -83.29% | -187.82% | |
Net Earnings / Revenue | -3.01% | -2.26% | |
Basic Earnings Per Share | -$0.13 | ||
Diluted Earnings Per Share | -$40.44K | -$0.13 | -$1.050M |
COMMON SHARES | |||
Basic Shares Outstanding | 52.62M | ||
Diluted Shares Outstanding | 52.62M |
Balance Sheet
Concept | 2021 Q4 | 2021 | 2020 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $47.92M | $47.92M | $908.7K |
YoY Change | 5173.08% | 5173.08% | |
Cash & Equivalents | $47.92M | $4.934M | |
Short-Term Investments | |||
Other Short-Term Assets | $17.58M | $17.58M | $198.2K |
YoY Change | 8770.67% | 8770.67% | |
Inventory | $550.0K | $550.0K | $15.00K |
Prepaid Expenses | $17.04M | $183.0K | |
Receivables | $42.00M | $42.00M | $9.395M |
Other Receivables | $0.00 | $0.00 | |
Total Short-Term Assets | $108.0M | $108.0M | $14.88M |
YoY Change | 626.05% | 9661.13% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $15.99M | $15.99M | $4.796M |
YoY Change | 233.47% | ||
Goodwill | $464.6M | $10.07M | |
YoY Change | 4514.28% | ||
Intangibles | $59.81M | $8.575M | |
YoY Change | 597.5% | ||
Long-Term Investments | $143.8M | ||
YoY Change | |||
Other Assets | $2.706M | $4.678M | $183.0K |
YoY Change | 1378.69% | ||
Total Long-Term Assets | $545.0M | $545.0M | $23.62M |
YoY Change | 2207.37% | 278.94% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $108.0M | $108.0M | $14.88M |
Total Long-Term Assets | $545.0M | $545.0M | $23.62M |
Total Assets | $653.1M | $653.1M | $38.50M |
YoY Change | 1596.21% | 350.58% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $3.110M | $3.110M | $1.044M |
YoY Change | 197.89% | 578.8% | |
Accrued Expenses | $8.690M | $8.690M | $2.572M |
YoY Change | 237.87% | 174.31% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $6.275M | $6.275M | $1.004M |
YoY Change | 525.0% | ||
Total Short-Term Liabilities | $21.96M | $21.96M | $5.451M |
YoY Change | 302.84% | 484.63% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $111.0M | $111.0M | $26.33M |
YoY Change | 321.5% | ||
Other Long-Term Liabilities | $6.428M | $14.80M | $29.21M |
YoY Change | -77.99% | -49.32% | |
Total Long-Term Liabilities | $117.4M | $125.8M | $26.33M |
YoY Change | 345.92% | 330.59% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $21.96M | $21.96M | $5.451M |
Total Long-Term Liabilities | $117.4M | $125.8M | $26.33M |
Total Liabilities | $147.7M | $147.7M | $31.78M |
YoY Change | 364.89% | 348.14% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | $33.00K | ||
YoY Change | |||
Common Stock | $505.3M | ||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $505.4M | $505.4M | $6.727M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $653.1M | $653.1M | $38.50M |
YoY Change | 1596.21% | 350.58% |
Cashflow Statement
Concept | 2021 Q4 | 2021 | 2020 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$3.556M | -$6.675M | -$21.28M |
YoY Change | -83.29% | -187.82% | |
Depreciation, Depletion And Amortization | $6.070M | $2.800M | |
YoY Change | 226.34% | ||
Cash From Operating Activities | -$15.05M | -$23.86M | -$78.88K |
YoY Change | 18984.69% | -548.76% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$3.905M | $3.990M | |
YoY Change | 85.5% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$11.36M | -$309.7M | $0.00 |
YoY Change | 115.45% | ||
Cash From Investing Activities | -$15.27M | -$316.6M | $0.00 |
YoY Change | 4460.34% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $415.0M | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -2.212M | 383.4M | 0.000 |
YoY Change | 17960.2% | ||
NET CHANGE | |||
Cash From Operating Activities | -15.05M | -23.86M | -78.88K |
Cash From Investing Activities | -15.27M | -316.6M | 0.000 |
Cash From Financing Activities | -2.212M | 383.4M | 0.000 |
Net Change In Cash | -32.53M | 42.98M | -78.88K |
YoY Change | 41144.93% | 8548.49% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$15.05M | -$23.86M | -$78.88K |
Capital Expenditures | -$3.905M | $3.990M | |
Free Cash Flow | -$11.15M | -$27.85M | |
YoY Change | -979.81% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1216000 | |
CY2021 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2021 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001813914 | |
CY2021 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2021 | dei |
Document Type
DocumentType
|
10-K | |
CY2021 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2021 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-12-31 | |
CY2021 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
CY2021 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2021 | dei |
Entity File Number
EntityFileNumber
|
001-39391 | |
CY2021 | dei |
Entity Registrant Name
EntityRegistrantName
|
CareMax, Inc. | |
CY2021 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2021 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
85-0992224 | |
CY2021 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1000 NW 57 Court | |
CY2021 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 400 | |
CY2021 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Miami | |
CY2021 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
FL | |
CY2021 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
33126 | |
CY2021 | dei |
City Area Code
CityAreaCode
|
786 | |
CY2021 | dei |
Local Phone Number
LocalPhoneNumber
|
360-4768 | |
CY2021 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2021 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2021 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2021 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2021 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
CY2021 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2021 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2021 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2021 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2021 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021Q2 | dei |
Entity Public Float
EntityPublicFloat
|
687516271 | |
CY2021 | dei |
Auditor Name
AuditorName
|
WithumSmith+Brown, PC | |
CY2021 | dei |
Auditor Location
AuditorLocation
|
Red Bank, New Jersey | |
CY2021 | dei |
Auditor Firm
AuditorFirmId
|
100 | |
CY2021Q4 | us-gaap |
Cash
Cash
|
47917000 | |
CY2020Q4 | us-gaap |
Cash
Cash
|
4934000 | |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
41998000 | |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
9395000 | |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
550000 | |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
15000 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
17040000 | |
CY2020Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
183000 | |
CY2021Q4 | cmax |
Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
|
539000 | |
CY2020Q4 | cmax |
Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
|
80000 | |
CY2020Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
274000 | |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
108044000 | |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
14881000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15993000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4796000 | |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
464566000 | |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
10068000 | |
CY2021Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
59811000 | |
CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
8575000 | |
CY2021Q4 | us-gaap |
Deferred Costs
DeferredCosts
|
1972000 | |
CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2706000 | |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
183000 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
653092000 | |
CY2020Q4 | us-gaap |
Assets
Assets
|
38503000 | |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3110000 | |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1044000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8686000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2572000 | |
CY2021Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
4000 | |
CY2020Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
149000 | |
CY2021Q4 | cmax |
Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
|
196000 | |
CY2020Q4 | cmax |
Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
|
643000 | |
CY2021Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
6275000 | |
CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
1004000 | |
CY2020Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
39000 | |
CY2021Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3687000 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21959000 | |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5451000 | |
CY2021Q4 | us-gaap |
Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
|
8375000 | |
CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
110960000 | |
CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
26325000 | |
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6428000 | |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
147722000 | |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
31776000 | |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
505327000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
33000 | |
CY2020Q4 | cmax |
Common Unit Par Or Stated Value Per Share
CommonUnitParOrStatedValuePerShare
|
0 | |
CY2020Q4 | us-gaap |
Common Unit Authorized
CommonUnitAuthorized
|
200 | |
CY2020Q4 | us-gaap |
Common Unit Issued
CommonUnitIssued
|
200 | |
CY2020Q4 | us-gaap |
Common Unit Outstanding
CommonUnitOutstanding
|
200 | |
CY2020Q4 | us-gaap |
Common Unit Issuance Value
CommonUnitIssuanceValue
|
223000 | |
CY2020Q4 | us-gaap |
Members Capital
MembersCapital
|
6504000 | |
CY2021Q4 | us-gaap |
Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest
LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
|
505370000 | |
CY2020Q4 | us-gaap |
Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest
LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
|
6727000 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
653092000 | |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38503000 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
295762000 | |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
103421000 | |
CY2021 | cmax |
Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
|
206747000 | |
CY2020 | cmax |
Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
|
66050000 | |
CY2021 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
57566000 | |
CY2020 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
17373000 | |
CY2021 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
4955000 | |
CY2020 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1067000 | |
CY2021 | cmax |
Corporate General And Administrative
CorporateGeneralAndAdministrative
|
40579000 | |
CY2020 | cmax |
Corporate General And Administrative
CorporateGeneralAndAdministrative
|
7748000 | |
CY2021 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
13216000 | |
CY2020 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1501000 | |
CY2021 | us-gaap |
Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
|
1522000 | |
CY2020 | us-gaap |
Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
|
0 | |
CY2021 | us-gaap |
Operating Expenses
OperatingExpenses
|
324585000 | |
CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
93739000 | |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28822000 | |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
9682000 | |
CY2021 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-4492000 | |
CY2020 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1659000 | |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-20757000 | |
CY2020 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
CY2021 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-5794000 | |
CY2020 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | |
CY2021 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-50000 | |
CY2020 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | |
CY2021 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1630000 | |
CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-451000 | |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1333000 | |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
0 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6516000 | |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
7572000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
159000 | |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-6675000 | |
CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
7572000 | |
CY2021 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | |
CY2020 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-29000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6675000 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7601000 | |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6675000 | |
CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
7601000 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52620980 | |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10796069 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
52620980 | |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
10796069 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.13 | |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.70 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.13 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
505370000 | |
CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-6675000 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.70 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4946000 | |
CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
7572000 | |
CY2020 | us-gaap |
Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
|
2100000 | |
CY2020 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
3691000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6727000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6727000 | |
CY2021 | cmax |
Net Income Loss Prior To Business Combination
NetIncomeLossPriorToBusinessCombination
|
-5185000 | |
CY2021 | cmax |
Stock Issued During Period Value For Contingent Issuable Stock Upon First Share Price Trigger On Earnout Shares
StockIssuedDuringPeriodValueForContingentIssuableStockUponFirstSharePriceTriggerOnEarnoutShares
|
39110000 | |
CY2021 | cmax |
Additional Paid In Capital Adjustments Related Reclassification Of Contingent Consideration Previously Liability Classified
AdditionalPaidInCapitalAdjustmentsRelatedReclassificationOfContingentConsiderationPreviouslyLiabilityClassified
|
45088000 | |
CY2021 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
6650000 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1341000 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
12883000 | |
CY2021 | cmax |
Net Income Loss After Business Combination
NetIncomeLossAfterBusinessCombination
|
-1490000 | |
CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
7572000 | |
CY2021 | us-gaap |
Depreciation
Depreciation
|
2813000 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
858000 | |
CY2021 | us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
10402000 | |
CY2020 | us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
643000 | |
CY2021 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
866000 | |
CY2020 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
177000 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1341000 | |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-20757000 | |
CY2020 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
CY2021 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-5794000 | |
CY2020 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | |
CY2021 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1630000 | |
CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-451000 | |
CY2021 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-331000 | |
CY2020 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
0 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3836000 | |
CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4208000 | |
CY2021 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
85000 | |
CY2020 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5000 | |
CY2021 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
768000 | |
CY2020 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-6000 | |
CY2021 | cmax |
Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
|
459000 | |
CY2020 | cmax |
Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
|
-248000 | |
CY2021 | cmax |
Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
|
235000 | |
CY2020 | cmax |
Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
|
-146000 | |
CY2021 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
1501000 | |
CY2020 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-12000 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-984000 | |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-686000 | |
CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
394000 | |
CY2021 | us-gaap |
Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
|
0 | |
CY2021 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
1574000 | |
CY2020 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | |
CY2021 | cmax |
Increase Decrease In Accrued Interest
IncreaseDecreaseInAccruedInterest
|
-145000 | |
CY2020 | cmax |
Increase Decrease In Accrued Interest
IncreaseDecreaseInAccruedInterest
|
0 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23856000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
5316000 | |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3990000 | |
CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2151000 | |
CY2021 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
309707000 | |
CY2020 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
2566000 | |
CY2021 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
2882000 | |
CY2020 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | |
CY2021 | cmax |
Payment Of Asset Purchase Agreement Holdback
PaymentOfAssetPurchaseAgreementHoldback
|
0 | |
CY2020 | cmax |
Payment Of Asset Purchase Agreement Holdback
PaymentOfAssetPurchaseAgreementHoldback
|
329000 | |
CY2020 | us-gaap |
Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
|
1897000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-316579000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6942000 | |
CY2021 | cmax |
Borrowing Under Revolving Loan Commitment
BorrowingUnderRevolvingLoanCommitment
|
0 | |
CY2020 | cmax |
Borrowing Under Revolving Loan Commitment
BorrowingUnderRevolvingLoanCommitment
|
4075000 | |
CY2021 | cmax |
Loan From Paycheck Protection Program
LoanFromPaycheckProtectionProgram
|
0 | |
CY2020 | cmax |
Loan From Paycheck Protection Program
LoanFromPaycheckProtectionProgram
|
2164000 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
415000000 | |
CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
12471000 | |
CY2020 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | |
CY2021 | cmax |
Reverse Recapitalization
ReverseRecapitalization
|
108435000 | |
CY2020 | cmax |
Reverse Recapitalization
ReverseRecapitalization
|
0 | |
CY2021 | us-gaap |
Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
|
125000000 | |
CY2020 | us-gaap |
Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
|
0 | |
CY2021 | cmax |
Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
|
27711000 | |
CY2020 | cmax |
Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
|
425000 | |
CY2021 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
7478000 | |
CY2020 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
0 | |
CY2021 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
487000 | |
CY2020 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
0 | |
CY2021 | us-gaap |
Distribution Made To Limited Liability Company Llc Member Cash Distributions Paid
DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid
|
0 | |
CY2020 | us-gaap |
Distribution Made To Limited Liability Company Llc Member Cash Distributions Paid
DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid
|
3691000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
383418000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2123000 | |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
42983000 | |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
497000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4934000 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4438000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
47917000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4934000 | |
CY2021 | us-gaap |
Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
|
188678000 | |
CY2020 | us-gaap |
Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
|
0 | |
CY2021 | cmax |
Contingent Consideration Issued In Business Combination
ContingentConsiderationIssuedInBusinessCombination
|
38348000 | |
CY2020 | cmax |
Contingent Consideration Issued In Business Combination
ContingentConsiderationIssuedInBusinessCombination
|
0 | |
CY2021 | cmax |
Purchase Of Non Controlling Interest Through Accounts Payable In Noncash Or Partial Noncash Transaction
PurchaseOfNonControllingInterestThroughAccountsPayableInNoncashOrPartialNoncashTransaction
|
0 | |
CY2020 | cmax |
Purchase Of Non Controlling Interest Through Accounts Payable In Noncash Or Partial Noncash Transaction
PurchaseOfNonControllingInterestThroughAccountsPayableInNoncashOrPartialNoncashTransaction
|
203000 | |
CY2021 | cmax |
Payroll Protection Program Loan Forgiveness
PayrollProtectionProgramLoanForgiveness
|
2164000 | |
CY2020 | cmax |
Payroll Protection Program Loan Forgiveness
PayrollProtectionProgramLoanForgiveness
|
0 | |
CY2021 | cmax |
Equity Warrant Consideration Issued
EquityWarrantConsiderationIssued
|
14533000 | |
CY2020 | cmax |
Equity Warrant Consideration Issued
EquityWarrantConsiderationIssued
|
0 | |
CY2021 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4423000 | |
CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1251000 | |
CY2021 | cmax |
Acquisition Of Business Financed Through Deferred Consideration
AcquisitionOfBusinessFinancedThroughDeferredConsideration
|
0 | |
CY2020 | cmax |
Acquisition Of Business Financed Through Deferred Consideration
AcquisitionOfBusinessFinancedThroughDeferredConsideration
|
450000 | |
CY2021 | cmax |
Purchase Of Property And Equipment Through Long Term Debt
PurchaseOfPropertyAndEquipmentThroughLongTermDebt
|
0 | |
CY2020 | cmax |
Purchase Of Property And Equipment Through Long Term Debt
PurchaseOfPropertyAndEquipmentThroughLongTermDebt
|
50000 | |
CY2021 | cmax |
Debt Issuance And Interest Costs Paid Through Long Term Debt
DebtIssuanceAndInterestCostsPaidThroughLongTermDebt
|
0 | |
CY2020 | cmax |
Debt Issuance And Interest Costs Paid Through Long Term Debt
DebtIssuanceAndInterestCostsPaidThroughLongTermDebt
|
399000 | |
CY2021 | cmax |
Extinguishment Of Long Term Debt Through New Debt Proceeds
ExtinguishmentOfLongTermDebtThroughNewDebtProceeds
|
0 | |
CY2020 | cmax |
Extinguishment Of Long Term Debt Through New Debt Proceeds
ExtinguishmentOfLongTermDebtThroughNewDebtProceeds
|
2500000 | |
CY2021 | cmax |
Acquisition Of Business Financed Through Long Term Debt
AcquisitionOfBusinessFinancedThroughLongTermDebt
|
0 | |
CY2020 | cmax |
Acquisition Of Business Financed Through Long Term Debt
AcquisitionOfBusinessFinancedThroughLongTermDebt
|
6051000 | |
CY2021 | cmax |
Number Of Wholly Owned Operating Multi Specialty Medical Centers
NumberOfWhollyOwnedOperatingMultiSpecialtyMedicalCenters
|
45 | |
CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment recognitions of long-lived assets; the valuation of the derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; settlements related to revenue and the revenue accrual and accrued expenses. Actual results could differ from those estimates.</span></p> | |
CY2021 | cmax |
Number Of Portfolio
NumberOfPortfolio
|
1 | |
CY2021 | us-gaap |
Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
|
true | |
CY2021 | us-gaap |
Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
|
true | |
CY2021 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company’s cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company believes it is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anthem, Inc. ("Anthem") represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s accounts receivable balance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020, respectively. Anthem represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s revenues for the three months ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s revenues for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve months ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p> | |
CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
106700000 | |
CY2021 | cmax |
Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
|
10900000 | |
CY2020 | cmax |
Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
|
10300000 | |
CY2021 | cmax |
Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
|
14700000 | |
CY2020 | cmax |
Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
|
11200000 | |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
10068000 | |
CY2021 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
454498000 | |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
464566000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
71141000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
11331000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
59811000 | |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
9494000 | |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
919000 | |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8575000 | |
CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
10400000 | |
CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
645000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
15134000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
12234000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
10199000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
8547000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
7616000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
6082000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
21902000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7892000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5909000 | |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3096000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15993000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4796000 | |
CY2021 | cmax |
Estimated Capital Expenditures To Complete Construction In Progress
EstimatedCapitalExpendituresToCompleteConstructionInProgress
|
500000 | |
CY2021 | us-gaap |
Depreciation
Depreciation
|
2800000 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
858000 | |
CY2021Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
4704000 | |
CY2020Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
377000 | |
CY2021Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
117236000 | |
CY2020Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
27329000 | |
CY2021Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
6275000 | |
CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
1004000 | |
CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
110960000 | |
CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
26325000 | |
CY2021 | us-gaap |
Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
|
Interest is payable on the outstanding loans under the Credit Facilities based on, at the option of the Company, either: (i) Eurocurrency (with a LIBOR floor of 0.75% per annum) plus variable spreads ranging from 2.75% to 3.50% per annum based on first lien net leverage ratio levels or (ii) the Alternate Base Rate (defined as the highest of (a) the Prime Rate (as defined in the Credit Agreement and established by the Agent), (b) the Federal Funds Rate (as defined in the Credit Agreement) plus 0.50% per annum, and (c) the LIBOR Quoted Rate (as defined in the Credit Agreement) plus 1.00% per annum, in each case, with a floor of 1.75% per annum), plus variable spreads ranging from 1.75% to 2.50% per annum based on first lien net leverage ratio levels. Accrued and unpaid interest is payable with respect to LIBOR loans on the last day of the interest period as selected by the Company but no later than three months, and with respect to Alternate Base Rate Loans, quarterly on the last business day of each of March, June, September and December. | |
CY2021 | us-gaap |
Line Of Credit Facility Commitment Fee Description
LineOfCreditFacilityCommitmentFeeDescription
|
An unused commitment fee is also payable with respect to the revolving credit facility and the delayed draw term loan facility ranging between 0.35% and 0.50% depending on the Company’s first lien net leverage ratio, and is payable quarterly in arrears with respect to the revolving credit facility and on the earliest of the termination of the delayed draw term loan facility, the six month anniversary of the Closing Date with respect to any delayed draw term loan commitments that have expired and otherwise after the end of the first full fiscal quarter after the Closing Date. | |
CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
6275000 | |
CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
6265000 | |
CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
8611000 | |
CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
11726000 | |
CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
89063000 | |
CY2021Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
121940000 | |
CY2021Q2 | cmax |
Capital Stock Par Or Stated Value Per Share
CapitalStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q2 | us-gaap |
Capital Units Authorized
CapitalUnitsAuthorized
|
261000000 | |
CY2021Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
260000000 | |
CY2021Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2021 | cmax |
Payment Of Offering Costs
PaymentOfOfferingCosts
|
12800000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
131000 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.82 | |
CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
131000 | |
CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
5.82 | |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1341000 | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
0 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1300000 | |
CY2021 | cmax |
Remaining Earnout Shares Excluded From Computation Of Basic Net Income Loss Per Share
RemainingEarnoutSharesExcludedFromComputationOfBasicNetIncomeLossPerShare
|
3200000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6675000 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7601000 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52620980 | |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10796069 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
52620980 | |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
10796069 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.13 | |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.70 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.13 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.70 | |
CY2021 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
20800000 | |
CY2021 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
CY2021Q4 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
CY2021 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
CY2021Q4 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
CY2021 | cmax |
Lessee Operating Lease Expiring Term Description
LesseeOperatingLeaseExpiringTermDescription
|
various times through 2031 | |
CY2021 | cmax |
Lessee Operating Lease Expiring Year
LesseeOperatingLeaseExpiringYear
|
2036 | |
CY2021 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
21000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
10087000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
10028000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
9715000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
9374000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
8685000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
58763000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
106652000 | |
CY2021 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
7200000 | |
CY2020 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1500000 | |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
126000 | |
CY2021 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
33000 | |
CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
159000 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.049 | |
CY2021 | cmax |
Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent
|
0.142 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.002 | |
CY2021 | cmax |
Effective Income Tax Rate Reconciliation Paycheck Protection Program Loan Forgiveness Percent
EffectiveIncomeTaxRateReconciliationPaycheckProtectionProgramLoanForgivenessPercent
|
0.081 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.221 | |
CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.025 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
2257000 | |
CY2021Q4 | cmax |
Deferred Tax Assets Warrant Liabilities
DeferredTaxAssetsWarrantLiabilities
|
2219000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
15982000 | |
CY2021Q4 | cmax |
Deferred Tax Assets Interest Carryforward
DeferredTaxAssetsInterestCarryforward
|
6962000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
27420000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
26128000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1292000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
1480000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
18000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
|
219000 | |
CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1717000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
425000 | |
CY2021Q2 | cmax |
Operating Loss Carryforwards Subject To Limitation
OperatingLossCarryforwardsSubjectToLimitation
|
43900000 | |
CY2021Q2 | cmax |
Operating Loss Carryforwards Subject To Business Expense Limitation
OperatingLossCarryforwardsSubjectToBusinessExpenseLimitation
|
21900000 | |
CY2021 | cmax |
Goodwill Amortization Period For Tax Purpose
GoodwillAmortizationPeriodForTaxPurpose
|
P15Y | |
CY2021Q4 | cmax |
Unrecognized Tax Benefits Reserve
UnrecognizedTaxBenefitsReserve
|
0 | |
CY2021 | us-gaap |
Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
|
1000000.0 | |
CY2021 | us-gaap |
Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
|
3000000.0 | |
CY2021Q4 | us-gaap |
Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
|
0 | |
CY2020Q4 | us-gaap |
Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
|
0 |